Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR
April 03 2014 - 8:00AM
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in
DNA-based diagnostics, announced today that a poster highlighting
preliminary results of a study in clear cell Renal Cell Carcinoma
(ccRCC) will be presented at the 105th Annual Meeting of the
American Association of Cancer Research ("AACR"), which will be
held in San Diego, California April 5-9, 2014.
Date: |
Sunday, April 6, 2014 |
Time: |
1pm – 5pm Pacific |
Session Title: |
Biomarkers of Tumor Metastasis |
Title: |
Identification of Genomic Alterations
Associated with Metastasis in Clear Cell Renal Cell Carcinoma |
The study, conducted by Cancer Genetics in collaboration with
researchers from Memorial Sloan-Kettering Cancer Center, was
designed to identify genomic copy number alterations by a
high-resolution approach (whole genome array-CGH) that could serve
as biomarkers for tumor metastasis in clear cell renal
carcinoma. The poster highlights results from 16 significant
aberrations that were identified to occur at higher frequencies in
metastatic compared to primary samples across unmatched and matched
analyses. The authors suggested that upon further validations,
including prospective studies, such aberrations could serve as
biomarkers of metastatic disease and, therefore, could be helpful
in risk-stratification and clinical management of low stage ccRCC
patients. Also in this study, metastatic site-specific
aberrations were identified that could be useful in defining
subclinical disease and to help understand the biology of those
metastasis.
Clear Cell Renal Cell Carcinoma accounts for approximately 70%
of all renal cortical neoplasms. Metastatic ccRCC is well
known for its aggressive nature and poor prognosis, with
approximately 20-40% of patients relapsing within 5 years of
nephrectomy. Also, metastatic ccRCC is largely refractory to
conventional treatments with a five-year survival rate of
approximately 8-9%, whereas targeted therapies are proven to
increase overall survival rates. Treatment options vary
depending on the site of metastasis.
This is the first year Cancer Genetics will have a presence at
AACR. Company representatives will be located at Booth
#445.
Cancer Genetics is also the primary sponsor
of the Society of American Asian Scientists in Cancer Research
annual dinner meeting, to be held on April 6th at The San
Diego Woman's Club at 6pm Pacific Time. Approximately 500
scientists, clinicians and researchers will gather to present
awards to the five top scientists, researchers and contributors to
cancer research.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please see
www.cancergenetics.com.
Forward Looking Statements: This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements pertaining
to future financial and/or operating results, future growth in
research, technology, clinical development and potential
opportunities for Cancer Genetics, Inc. products and services,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to, statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, maintenance
of intellectual property rights and other risks discussed in the
Company's Form 10-K for the year ended December 31, 2013 and other
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking
statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024